How Common Is CIDP, and Who Is Most Likely to Get It?

Chronic inflammatory demyelinating polyneuropathy (CIDP) is considered a rare disease. While it can affect people of any age or sex, rates are higher in older adult men ^[1][2]. Published population-based studies from multiple countries estimate that between 1 and 9 people out of every 100,000 have diagnosed CIDP ^[3], though recent data looking at insurance claims in the United States suggests it could be somewhat more common ^[4]. However, because CIDP can be challenging to identify correctly, broad demographic statistics are only averages—they do not cause the disease, predict how severe it will be, or rule a diagnosis in or out for any specific person.

How Many People Have CIDP?

When doctors look at how common a disease is, they evaluate two main metrics: incidence (the number of newly diagnosed cases per year) and prevalence (the total number of people currently living with the condition).

Because CIDP is rare, numbers vary widely based on where a study is conducted, the age structure of the population, access to neuromuscular specialists, and how the researchers count cases.

• Averages from clinical studies: In multiple population-based studies globally, the prevalence of CIDP typically ranges from 0.8 to 8.9 cases per 100,000 people ^[3]. A large meta-analysis pooling many of these studies found an average prevalence of about 2.8 per 100,000 ^[5].
• New cases (incidence): Across these clinical studies, about 0.2 to 1.6 new cases per 100,000 people are diagnosed each year ^[3].
• United States claims estimates: A 2023 study looking at U.S. healthcare claims estimated a much higher prevalence of 23.3 per 100,000 people, which mathematically extrapolates to roughly 77,000 Americans, with an incidence of 2.8 new cases per 100,000 each year ^[4].

Why are the estimates so different? The variation largely comes down to how cases are defined ^[5]. Studies looking at medical insurance codes (like the U.S. estimate) often capture higher numbers, but they may inadvertently include patients who have other types of nerve damage, duplicate records, or miscoding ^[6][4]. Studies that require strict clinical criteria tend to report lower numbers ^[7].

Who is Most Likely to Get It?

While CIDP can affect anyone, certain demographic groups develop the condition more frequently.

• Age: CIDP is primarily a disease of adults, and the likelihood of developing it increases as you get older. Studies show that the average age of diagnosis is around 58 years old ^[1]. The incidence is substantially higher in people over the age of 50 compared to younger adults ^[2].
• Sex: In most large population studies, men are diagnosed with CIDP more often than women ^[1][2]. For example, one large Dutch study found the incidence in men to be three times higher than in women ^[2], while a South Korean study found a male-to-female ratio of 1.7 to 1 ^[1].
• Children (Pediatric CIDP): Although it is rare, children and adolescents can get CIDP ^[8]. When young children develop symptoms of severe demyelination (damage to the protective myelin sheath covering the nerves), doctors must carefully differentiate pediatric CIDP from hereditary neuropathies (genetic nerve disorders). It is important to note that the absence of a known family history does not rule out a genetic cause, as family history can sometimes be unrecognized or absent ^[9].

These demographic associations do not imply that CIDP is preventable through behavior or lifestyle, nor do they predict your individual outcome or response to treatment.

Why Statistics Don’t Define Your Diagnosis

If you are a young woman or a teenager, you might wonder if you can still have CIDP despite the statistics. The answer is yes. Epidemiology tells us about broad population trends, but it cannot confirm or exclude an individual diagnosis.

Because CIDP lacks a single, definitive blood test, diagnosing it correctly can be challenging. In fact, research from specialized referral centers shows that diagnostic errors happen in both directions:

• Missed diagnoses: In one specialized clinic studying patients with confirmed CIDP, nearly 70% had initially been given a different diagnosis before finally being identified correctly ^[10].
• Over-diagnosis: Conversely, in another referral study, about a third of patients referred to specialists with a “confirmed” CIDP diagnosis were later found to have a different condition entirely ^[11].

(Note: These high percentages reflect challenging cases sent to specialized referral centers, not necessarily the error rates for all people evaluated for CIDP.)

Living with diagnostic uncertainty for a rare disease can be highly stressful. This difficulty is why your doctor’s evaluation matters far more than your age or sex. No single test confirms CIDP ^[12]. Instead, diagnosis relies on a combination of:

• Clinical symptoms: The specific pattern of your progressive weakness and sensory changes.
• Nerve conduction studies: Tests (often performed alongside an electromyogram, or EMG) that measure how fast and well electrical signals travel through your nerves, looking for objective evidence of demyelination.
• Supportive tests: A spinal fluid analysis (collecting cerebrospinal fluid via a lumbar puncture to look for elevated protein levels), nerve imaging, or genetic testing. Note that spinal fluid results are only supportive; they are not definitive and can sometimes be normal even in CIDP. Response to immune treatments is also sometimes considered, but a positive response alone does not prove you have CIDP.

Changes in international diagnostic guidelines—most recently updated in 2021 by the European Academy of Neurology and Peripheral Nerve Society (EAN/PNS)—mean the exact criteria for what “counts” as CIDP continue to evolve over time, and atypical variants may require specialist interpretation ^[7].